We recently published 10 Stocks Ending February With a Bang. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) was one of the best performers on Friday. BioCryst surged by 10.76 percent on Friday to close at $8.75 apiece, as investor sentiment was bolstered by its swing to profitability for the first time last year. In an updated report, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said that it swung to a net income of $263.86 million last year from an $88.88 million net loss in 2024. Total revenues soared by ...

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best small-cap stocks with huge growth potential. On February 18, Evercore ISI resumed coverage of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) with a Buy rating and set a price target of $17.00. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) also received a rating update from Bank of America Securities on January 27, which reaffirmed a Buy rating on the stock with a price target of $15. Cantor Fitzgerald Sees Deal Activity and Pipeline Progress as Key ...

BioCryst highlighted the FDA’s approval in December 2025 of ORLADEYO oral pellets for children ages 2 to less than 12 . Chief Development Officer Dr. Bill Sheridan said the company is continuing marketing authorization applications in other major regions. Management described the unmet need as significant, noting that HAE and related attacks are underdiagnosed in younger children and that prophylaxis usage is about half that of adults.Gayer emphasized patient persistence and a “super responder” population f ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant advancement with the potential for substantial social benefits [8]

The market expects Harrow (HROW) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on March 2, might help the stock move higher if these key numbers are better tha ...

Company Overview - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) specializes in treatments for rare diseases, including an oral medication for hereditary angioedema and an injectable flu therapy [3] - The company is also engaged in discovering and testing new drugs for allergic and immunological conditions [3] Recent Developments - On January 23, BioCryst finalized a $700 million acquisition of Astria Therapeutics, which adds navenibart to its portfolio [3] - Navenibart is a long-acting Phase 3 therapy for hereditary angioedema, a rare genetic condition causing sudden, painful swelling [3] Market Sentiment - Jim Cramer expressed a negative outlook on BioCryst, advising investors to stay away from the stock, indicating it has been underperforming for a long time [1] - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to BioCryst [4]

Core Insights - Korro Bio, Inc. (KRRO) shares increased by 13.9% to close at $13.31, with a notable 45.9% gain over the past four weeks, driven by strong trading volume [1][2] Company Developments - The rise in stock price is attributed to growing investor confidence in Korro's pipeline diversification, particularly with the introduction of KRRO-121 as a significant second asset alongside KRRO-110, an RNA-editing therapeutic candidate [2] - KRRO-121 is designed as a subcutaneously administered, GalNAc-conjugated RNA-editing therapy aimed at generating a de novo protein variant, with a first-in-human regulatory filing anticipated in the second half of 2026 [2] - Korro is also transitioning its AATD program to a GalNAc-conjugated construct, with a development candidate nomination expected in the first half of 2026, while advancing additional liver-targeted, subcutaneous GalNAc programs in cardiometabolic indications [2] Financial Expectations - The company is projected to report a quarterly loss of $1.86 per share, reflecting a year-over-year increase of 17.7%, with revenues expected to be $1.5 million, down 33.9% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Korro Bio, Inc. holds a Zacks Rank of 3 (Hold) within the Zacks Medical - Drugs industry, which includes other companies like BioCryst Pharmaceuticals (BCRX), that closed 0.2% higher at $6.67, but has seen a return of -14.6% over the past month [5] - BioCryst's consensus EPS estimate has decreased by 7.7% over the past month to $0.06, representing a year-over-year change of 146.2% [6]

Core Viewpoint - The proposed sale of Astria Therapeutics, Inc. to BioCryst Pharmaceuticals, Inc. is under investigation to assess whether the offered consideration adequately values Astria [1] Group 1: Transaction Details - Shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria they own [1] - The law firm Kahn Swick & Foti, LLC is investigating the adequacy of this consideration and the process leading to the proposed sale [1] Group 2: Legal Rights and Contact Information - Individuals who believe the transaction undervalues Astria can contact KSF Managing Partner Lewis S. Kahn for discussions regarding their legal rights [2] - KSF offers a no-obligation consultation for those interested in the proposed sale [2]

Core Viewpoint - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is highlighted as a promising small-cap stock with significant upside potential, particularly following the FDA approval of Orladeyo for pediatric patients with hereditary angioedema [1][2]. Group 1: FDA Approval and Product Details - On December 12, BioCryst Pharmaceuticals announced that the FDA approved its New Drug Application for an oral pellet formulation of ORLADEYO (berotralstat) for pediatric patients aged 2 to <12 years with hereditary angioedema [2]. - ORLADEYO is noted as the first and only targeted oral prophylactic therapy for this age group, which previously had limited treatment options that were burdensome [2]. - The company also reported that a capsule formulation of ORLADEYO was approved in December 2020 for patients aged 12 years and older, and it is now approved in over 45 countries [3]. Group 2: Investment Outlook - H.C. Wainwright raised the price target for BioCryst Pharmaceuticals from $30 to $32 and reaffirmed a Buy rating, citing the approval of Orladeyo as a significant factor for this update [1]. - The company is recognized for its innovative approach in biotechnology, focusing on structure-guided drug design to develop therapies for rare diseases [3].

Group 1: Artiva Biotherapeutics - Artiva is developing AlloNK, a natural killer (NK) cell-based therapy for autoimmune diseases and cancers, with ongoing clinical trials for conditions like refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) [2][6] - The FDA granted Fast Track designation to AlloNK for refractory RA, highlighting its potential to meet the needs of over 150,000 U.S. patients who have not responded to existing treatments [6] - Recent data from 32 patients treated with AlloNK showed no cases of cytokine release syndrome or neurotoxicity, with all patients achieving complete B-cell depletion by Day 13 [7] Group 2: Market Potential and Analyst Ratings - Wedbush analyst Martin Fan projects a price target of $23 for Artiva, indicating a potential upside of approximately 600% over the next 12 months, supported by a Strong Buy consensus from analysts [10] - The SPDR S&P Biotech ETF (XBI) has increased by about 37% year-to-date, suggesting a growing interest in the biotech sector amid a pause in AI market leadership [4] - Artiva's shares are currently trading at $3.30, which is below its cash value of $5 per share, indicating potential for substantial appreciation as clinical data emerges [10] Group 3: BioCryst Pharmaceuticals - BioCryst has transitioned into a profitable biotech company, driven by its focus on rare diseases and the success of its drug Orladeyo, which generated $159.1 million in net revenue for Q3 2025, a 37% year-over-year increase [14][15] - The FDA recently approved an oral pellet formulation of Orladeyo for pediatric patients, expanding its market reach and potential revenue, with estimates suggesting it could generate $1 billion in peak annual revenue by 2029 [15] - BioCryst's stock is trading at $7.57, with an average price target of $19.27, implying a potential gain of 154% over the next 12 months, supported by a Strong Buy consensus from analysts [19]